Sutro Biopharma (STRO) Total Current Liabilities (2017 - 2025)
Sutro Biopharma (STRO) has disclosed Total Current Liabilities for 9 consecutive years, with $75.1 million as the latest value for Q4 2025.
- Quarterly Total Current Liabilities fell 43.03% to $75.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $75.1 million through Dec 2025, down 43.03% year-over-year, with the annual reading at $75.1 million for FY2025, 43.03% down from the prior year.
- Total Current Liabilities hit $75.1 million in Q4 2025 for Sutro Biopharma, up from $71.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $133.0 million in Q1 2025 to a low of $22.7 million in Q1 2021.
- Historically, Total Current Liabilities has averaged $72.8 million across 5 years, with a median of $69.5 million in 2023.
- Biggest five-year swings in Total Current Liabilities: soared 93.65% in 2024 and later crashed 45.24% in 2025.
- Year by year, Total Current Liabilities stood at $41.7 million in 2021, then skyrocketed by 59.45% to $66.5 million in 2022, then surged by 40.87% to $93.7 million in 2023, then soared by 40.69% to $131.9 million in 2024, then plummeted by 43.03% to $75.1 million in 2025.
- Business Quant data shows Total Current Liabilities for STRO at $75.1 million in Q4 2025, $71.9 million in Q3 2025, and $74.2 million in Q2 2025.